AI주식인사이트AI Stock Insight
B

휴온스

243070KOSDAQ의약품 제조업

65.2 / 100

Reference Date: 2026-06-10

Financial Score22.5 / 40
News Sentiment18.7 / 25
Momentum10.0 / 20
Disclosure14.0 / 15
AI Analysis: ROE significantly exceeds the industry average but Operating Profit is on a declining trend. Rose 5.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hoonswell, established in 1965, is a pharmaceutical company operating in specialty drugs, beauty & wellness, and contract manufacturing (CMO). Key products include local anesthetics, functional food supplements, and medical devices, with exports to the U.S. via FDA approval. The company expanded its global presence by launching its second plant in Cheongju in 2024.

Number of Employees

1,087people

Average Salary

58.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
8.66Industry Average 11.936.5Point

Lower than industry avg (good)

PBR
0.88Industry Average 0.894.0Point

In line with industry avg

ROE
11.04Industry Average 4.017.0Point

2.8x industry avg (excellent)

Debt Ratio
22.82Industry Average 12.430.5Point

1.8x industry avg (risky)

Trend 2023~20254.5 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲6.0% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼7.1% (2-year basis)

ROE Trend
2.5 / 4

Avg ROE 12.0% (declining, 3yr)

Detailed News Sentiment

22 totalPositive 17Neutral 2Negative 3Average Sentiment Score 74.8

Detailed Momentum

52-week position5.0Point

52w mid range (43%)

Current 30,550Won52-week high 38,20052-week low 24,750
1-month return4.0Point

1m +5.89% (slight rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

17 totalPositive 2Neutral 15Negative 0
  • Neutral[기재정정]주주명부폐쇄기간또는기준일설정2026-06-04
  • Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-06-04
  • Neutral[기재정정]주요사항보고서(회사합병결정)2026-06-04
  • Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-05-28
  • Neutral[기재정정]주요사항보고서(회사합병결정)2026-05-28